The Stellarex drug-coated balloon beat percutaneous transluminal angioplasty for primary patency and freedom from clinically-driven target lesion revascularization at 1 year in a randomized trial presented at the Amputation Prevention Symposium. The device is designed for the superficial femoral and popliteal arteries and is expected to be introduced to the U.S. in 2017.